For more information on this and other stories, visit www.newsinfusion.com
October 22, 2008 - Preliminary results from a large safety study, called the Vaccine Safety Datalink (VSD) project, presented for the first time today by the Centers for Disease Control and Prevention (CDC) at the Advisory Committee on Immunization Practices (ACIP) meeting did not find statistically significant risk for any of the pre-specified adverse events following vaccination with GARDASILÒ [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] compared to those who were not vaccinated. This finding was based on more than 375,000 doses of GARDASIL administered.
GARDASIL is an important tool to help prevent cervical cancer caused by HPV types 16 and 18 for girls and young women. About 30 women every day are diagnosed with cervical cancer in the United States. An estimated eight out of 10 women will become infected with HPV in their lifetime. For most people, HPV clears on its own. But for some women who dont clear certain types of the virus, cervical cancer can develop. And theres no way to predict who will or wont clear the virus. While half of all women diagnosed with cervical cancer are between 35 and 55 years old, many of these women could have been exposed to cancer-causing HPV types in their teens and 20s.
GARDASIL is indicated to help prevent cervical, vaginal and vulvar cancers, precancerous and low-grade lesions, and genital warts caused by HPV types 6, 11, 16 and 18. The CDCs ACIP recommends routine 3-dose vaccination of girls aged 11-12 years and also for girls and women ages 13 through 26 years who have not yet been vaccinated. The additional safety data from the VSD project supports the ACIP and medical society recommendations from the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the American Academy of Family Physicians.
you can so tel theyy arentt actually givingg the shott.
laurennRubess1995 3 years ago